Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Martin Pool"'
Autor:
Imke Boekestijn, Matthias N. van Oosterom, Paolo Dell’Oglio, Floris H. P. van Velden, Martin Pool, Tobias Maurer, Daphne D. D. Rietbergen, Tessa Buckle, Fijs W. B. van Leeuwen
Publikováno v:
Cancer Imaging, Vol 22, Iss 1, Pp 1-15 (2022)
Abstract Molecular imaging technologies are increasingly used to diagnose, monitor, and guide treatment of i.e., cancer. In this review, the current status and future prospects of the use of molecular imaging as an instrument to help realize precisio
Externí odkaz:
https://doaj.org/article/709274a036bc47ec8d3f1e9d70798681
Autor:
Danique Giesen, Marjolijn N. Lub-de Hooge, Marcel Nijland, Helen Heyerdahl, Jostein Dahle, Elisabeth G. E. de Vries, Martin Pool
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract [177Lu]Lu-DOTA-NNV003, a radioimmunoconjugate targeting CD37, is developed as novel radioimmunotherapy (RIT) treatment for patients with B cell non-Hodgkin’s lymphoma (NHL). Since patients are at risk for developing hematological toxicitie
Externí odkaz:
https://doaj.org/article/27fc17b8666243629d517ab3e7966443
Autor:
Paolo Dell’Oglio, Danny M. van Willigen, Matthias N. van Oosterom, Kevin Bauwens, Fabian Hensbergen, Mick M. Welling, Huijbert van der Stadt, Elise Bekers, Martin Pool, Pim van Leeuwen, Tobias Maurer, Fijs W. B. van Leeuwen, Tessa Buckle
Publikováno v:
EJNMMI Research, Vol 12, Iss 1, Pp 1-8 (2022)
Abstract Background With the rise of prostate-specific membrane antigen (PSMA) radioguided surgery, which is performed using a microdosing regime, demand for visual target confirmation via fluorescence guidance is growing. While proven very effective
Externí odkaz:
https://doaj.org/article/7f23ca2d80ae44559c65dc4d0cb5c20e
Autor:
Maaike Dotinga, Dennis Vriens, Floris H. P. van Velden, Mette K. Stam, Jan W. T. Heemskerk, Petra Dibbets-Schneider, Martin Pool, Daphne D. D. Rietbergen, Lioe-Fee de Geus-Oei, Ellen Kapiteijn
Publikováno v:
Diagnostics, Vol 12, Iss 12, p 3154 (2022)
Background: Management of patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) is a challenge as I-131 therapy is deemed ineffective while standard-of-care systemic therapy with tyrosine kinase inhibitor (TKI) lenvatinib is
Externí odkaz:
https://doaj.org/article/a3e65c56397e47b3a4b9c7a4a1606cf9
Autor:
Martin Pool, Elisabeth G.E. de Vries, Olga Vasiljeva, Margaret Nguyen, Bruce Howng, Irina Popova, Marjolijn N. Lub-de Hooge, Linda N. Broer, Danique Giesen
In vivo quantification of ��Zr-CX-072, ��Zr-PbCtrl and ��Zr-CX-075 PET imaging.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2055791a2ea8a31f0a1c7f4a8f1637f3
https://doi.org/10.1158/1078-0432.22477196
https://doi.org/10.1158/1078-0432.22477196
Autor:
Martin Pool, Elisabeth G.E. de Vries, Olga Vasiljeva, Margaret Nguyen, Bruce Howng, Irina Popova, Marjolijn N. Lub-de Hooge, Linda N. Broer, Danique Giesen
Figure legends for Figure S1-S6.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c29bd15c5014f9f18675a465412c731
https://doi.org/10.1158/1078-0432.22477184
https://doi.org/10.1158/1078-0432.22477184
Autor:
Martin Pool, Elisabeth G.E. de Vries, Olga Vasiljeva, Margaret Nguyen, Bruce Howng, Irina Popova, Marjolijn N. Lub-de Hooge, Linda N. Broer, Danique Giesen
Purpose:Probody therapeutic CX-072 is a protease-activatable antibody that is cross-reactive with murine and human programmed death-ligand 1 (PD-L1). CX-072 can be activated in vivo by proteases present in the tumor microenvironment, thereby potentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::603414c0ab3d3c305d830a4337bd47af
https://doi.org/10.1158/1078-0432.c.6529592
https://doi.org/10.1158/1078-0432.c.6529592
Autor:
Daan G J, Linders, Okker D, Bijlstra, Laura C, Fallert, Denise E, Hilling, Ethan, Walker, Brian, Straight, Taryn L, March, A Rob P M, Valentijn, Martin, Pool, Jacobus, Burggraaf, James P, Basilion, Alexander L, Vahrmeijer, Peter J K, Kuppen
Publikováno v:
Molecular imaging and biology.
The majority of breast cancer patients is treated with breast-conserving surgery (BCS) combined with adjuvant radiation therapy. Up to 40% of patients has a tumor-positive resection margin after BCS, which necessitates re-resection or additional boos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a688bc6ccc98a95520b50666b2dccee4
https://pubmed.ncbi.nlm.nih.gov/36002710
https://pubmed.ncbi.nlm.nih.gov/36002710
Autor:
Marjolijn N. Lub-de Hooge, Olga Vasiljeva, Margaret Nguyen, Martin Pool, Linda N. Broer, Danique Giesen, Irina Popova, Bruce Howng, Elisabeth G.E. de Vries
Publikováno v:
Clinical Cancer Research, 26(15), 3999-4009. AMER ASSOC CANCER RESEARCH
Purpose:Probody therapeutic CX-072 is a protease-activatable antibody that is cross-reactive with murine and human programmed death-ligand 1 (PD-L1). CX-072 can be activated in vivo by proteases present in the tumor microenvironment, thereby potentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::713d0874ebf2f9fabbac565be71dfd46
https://doi.org/10.1158/1078-0432.ccr-19-3137
https://doi.org/10.1158/1078-0432.ccr-19-3137
Autor:
Martin Pool, Elisabeth G.E. de Vries, Fabrizia Fusetti, Harry J.M. Groen, Esméé Joosten, Suzanne van Cooten, Douwe F. Samplonius, Rudolf S N Fehrmann, Marcel A. T. M. van Vugt, Marieke Everts, H. Rudolf de Boer, Wijnand Helfrich
Publikováno v:
ONCOGENE, 38(9), 1477-1488. Nature Publishing Group
Tumor responses to cancer therapeutics are generally monitored every 2-3 months based on changes in tumor size. Dynamic biomarkers that reflect effective engagement of targeted therapeutics to the targeted pathway, so-called "effect sensors", would f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb55dd3a695b0578cab6a82dbbd6538c
https://doi.org/10.1038/s41388-018-0522-7
https://doi.org/10.1038/s41388-018-0522-7